Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cyclophosphamide + Interferon alpha-2b + Ipilimumab + SV-BR-1-GM|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Interferon alpha-2b||Intron A||Alfatronol|Alfatronol|interferon alpha-2b|Sch 30500|
|Ipilimumab||Yervoy||BMS-734016||CTLA4 Antibody 16 Immune Checkpoint Inhibitor 95||Yervoy (ipilimumab) is an antibody that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), causing increased T-cell activation (PMID: 28891423). Yervoy (ipilimumab) is FDA approved for use in patients with metastatic melanoma, including patients 12 years or older, and in combination with Opdivo (nivolumab) for intermediate or poor-risk renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (including patients 12 years or older), hepatocellular carcinoma previously treated with Nexavar (sorafenib), in combination with Opdivo (nivolumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic non-small cell lung cancer without EGFR or ALK alterations, and in combination with Opdivo (nivolumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK alterations (FDA.gov).|
|SV-BR-1-GM||SV-BR-1-GM is a vaccine comprised of breast cancer cells from the cell line, SV-BR-1, and granulocyte-macrophage colony-stimulating factor, which may lead to an immune response against breast cancer cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03328026||Phase Ib/II||Cyclophosphamide + Interferon alpha-2b + Ipilimumab + SV-BR-1-GM Cyclophosphamide + Interferon alpha-2b + Pembrolizumab + SV-BR-1-GM||Rollover Study of SV-BR-1-GM in Combination With Ipilimumab or Pembrolizumab||Recruiting|